RETAIN: Study of Inflammatory and Physiological Profiles of Healthy and Diseased Lung

Sponsor
Guy's and St Thomas' NHS Foundation Trust (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06144476
Collaborator
King's College London (Other)
230
1
69
3.3

Study Details

Study Description

Brief Summary

There are over 700,000 UK hospital admissions every year with lung disease symptoms. Two of the most common lung diseases contributing to these numbers are asthma and chronic obstructive pulmonary disease (COPD). The immunopathology of these diseases is not fully understood. Matched samples from the respiratory tract and circulation will be used to identify immune patterns throughout the respiratory system to elucidate the immunopathology of airway disease.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    In this observational study, we will be enrolling patients with diagnosed or suspected airways disease who are over 18 years old, as well as age matched healthy volunteers with no significant illness. Participants will be asked if they consent to enter the study, invited at clinically relevant time points (treatment change, disease exacerbation etc.) and to optional bronchoscopy visits. It is expected that participants will be seen yearly with any additional exacerbation/treatment visits also recorded. Research visits will occur at King's College London and the Guys and St Thomas' NHS Foundation Trust (GSTFT), with all bronchoscopy visits occurring within GSTFT

    1. Disease specific questionnaires.

    2. Lung function tests including spirometry or oscillometry (if not performed previously within 6 months)

    3. Sputum collection

    4. Nasal sampling including nasosorption, nasal brushing, nasal lavage, or nasopharyngeal swabs

    5. Exhaled breath

    6. Blood samples (<6 tablespoons)

    Optional

    1. Bronchoscopy involving a flexible fibreoptic camera passed into the lungs to collect bronchoalveolar lavage, bronchosorption, bronchial brushings and bronchial biopsies.

    2. To repeat these procedures at later time - expected once per year or at times of clinically relevant changes

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    230 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Study of Inflammatory and Physiological Profiles of Healthy and Diseased Lung
    Anticipated Study Start Date :
    Dec 1, 2023
    Anticipated Primary Completion Date :
    Aug 31, 2026
    Anticipated Study Completion Date :
    Aug 31, 2029

    Arms and Interventions

    Arm Intervention/Treatment
    Airways Disease

    Patients with or suspected airways disease including COPD or asthma

    Healthy Volunteers

    Participants with no significant illness

    Outcome Measures

    Primary Outcome Measures

    1. Blood samples for presence of airway disease immune endotypes [6 years]

      Blood samples taken to assess inflammatory mediators to determine airway disease severity. Physiological and inflammatory characterisation of participants with known or suspected airway disease at stable state, compared to healthy volunteers with the aim to identify distinct immune endotypes in airways disease

    Secondary Outcome Measures

    1. Blood samples for stability of airway disease immune endotypes [6 years]

      To assess the stability of blood inflammatory mediators to identify continuing airway disease endotypes. Longitudinal analysis of physiological and inflammatory characteristics in participants with known or suspected airway disease at stable state, compared to healthy volunteers over time.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Participant is willing and able to give informed consent for participation in the study

    • Aged 18 years or above

    • Patient: known or suspected airway disease

    • Healthy volunteer: considered to be in good health with no significant comorbidity (immune disorder, cancer etc.)

    Exclusion Criteria:
    • Known or suspected current pulmonary tuberculosis, HIV (human immunodeficiency virus), Hepatitis B Virus, Hepatitis C Virus.

    • Surgery within the preceding 6 weeks

    • Participants who are pregnant

    • History of psychiatric, medical, or surgical disorders that in the opinion of the chief investigator may interfere with sample collection, undergo a bronchoscopy, or may compromise study completion or data collection

    • Alcohol or recreational drug abuse

    • Diagnosis of immunodeficiency requiring treatment

    • Unable to provide written informed consent

    • Unable to read or write English

    • Be considered, in the opinion of the investigator, to be an unsuitable candidate for the study

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Guy's & St Thomas' NHS Foundation Trust London United Kingdom SE1 9RT

    Sponsors and Collaborators

    • Guy's and St Thomas' NHS Foundation Trust
    • King's College London

    Investigators

    • Principal Investigator: Mona Bafadhel, Prof, GSTT and KCL

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Guy's and St Thomas' NHS Foundation Trust
    ClinicalTrials.gov Identifier:
    NCT06144476
    Other Study ID Numbers:
    • 322540
    First Posted:
    Nov 22, 2023
    Last Update Posted:
    Nov 22, 2023
    Last Verified:
    Nov 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Guy's and St Thomas' NHS Foundation Trust

    Study Results

    No Results Posted as of Nov 22, 2023